Allscripts Healthcare Solutions recently announced that its flagship Veradigm unit has entered into a long-term strategic partnership with Komodo Health. The goal of the collaboration is to advance health care research by using an electronic health record system and Komodo’s Healthcare Map to find ways to reduce disease burden.
San Francisco-based Komodo Health is a provider of life-saving therapies by improving the standard of care, delivering care management, and providing extensive research in patient data.
Veradigm’s integrated data systems and service business combines data-driven clinical insights for clinical workflow, analytics, research, and media. Allscripts introduced the service in 2018.
Allscripts recently acquired the American College of Cardiology’s cardiology and diabetes registry assets, which could extend Veradigm’s EHR-enabled ambulatory research network. It also signed an agreement with WOMBA, which will use Veradigm’s eChart Coruier to provide medical chart records for health care providers.
The company has seen a lot of developments in its EHR platform in 2019 as well. Allscripts’ 2bPrecise partnered with Q-State Biosciences to combine Q-State’s whole-genome and whole-exome sequencing capabilities with 2BPrecise’s cloud-based platform. Allscripts also introduced its FollowMyHealth as a platform for existing Microsoft HealthVault users to export their existing data and continue tracking their health online or through mobile apps.
All of this leads Zacks to believe that the positive developments will boost the Zacks Rank #3 (Hold) stock, which has declined 35.8% compared with the general industry’s 8.1% fall. However, it believes that a few better-ranked stocks in the medical space are DENTSPLY SIRONA, Intuitive Surgical, and Baxter International, each of which carry a Zacks Rank #2 (Buy).
Read the full article here.